Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | March 31, 2021 | April 02, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | November 16, 2011 | November 20, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 26,998.916 |
Reported balance
After 2021-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 574.212 · Balance 26,998.916 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
VERTEX PHARMACEUTICALS INC / MA
Report date November 16, 2011 · Filed November 20, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,873 |
Reported balance
After 2012-11-16 transaction · row 1
1 source rowRow 1 · 2012-11-16 · Sale · Disposed 10,850 · Balance 200,873 F1: Open market sales reported on this line occurred at a weighted average price of $41.76 (range $41.63 to $41.95). F2: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market sales reported on this line occurred at a weighted average price of $41.76 (range $41.63 to $41.95).
F2: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2021 Filed Apr 2, 2021 17:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 574.212 | $63.13 | $36,250.00 |
DisclosureSEC source: 0000014272-21-000119 · wf-form4_161738381347414.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,998.916 Underlying: Common Stock, $0.10 par value · 574.212 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,054.171 | $62.21 | $189,999.98 |
DisclosureSEC source: 0000014272-21-000049 · wf-form4_161239782124115.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,424.704 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 584.395 | $62.03 | $36,250.02 |
DisclosureSEC source: 0000014272-21-000019 · wf-form4_160989542864904.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,187.894 Underlying: Common Stock, $0.10 par value · 584.395 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 601.261 | $60.29 | $36,250.03 |
DisclosureSEC source: 0000014272-20-000267 · wf-form4_160167068073141.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,433.803 Underlying: Common Stock, $0.10 par value · 601.261 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 616.497 | $58.80 | $36,250.02 |
DisclosureSEC source: 0000014272-20-000212 · wf-form4_159372340624194.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,667.561 Underlying: Common Stock, $0.10 par value · 616.497 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 650.341 | $55.74 | $36,250.01 |
DisclosureSEC source: 0000014272-20-000144 · wf-form4_158586072702330.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,895.03 Underlying: Common Stock, $0.10 par value · 650.341 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 23:05 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,018.268 | $62.95 | $189,999.97 |
DisclosureSEC source: 0000014272-20-000061 · wf-form4_158085750018445.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,244.689 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 564.73 | $64.19 | $36,250.02 |
DisclosureSEC source: 0000014272-20-000017 · wf-form4_157809533063118.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,105.355 Underlying: Common Stock, $0.10 par value · 564.73 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 714.849 | $50.71 | $36,249.99 |
DisclosureSEC source: 0000014272-19-000176 · wf-form4_157004948932454.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,422.827 Underlying: Common Stock, $0.10 par value · 714.849 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 767.536 | $45.35 | $34,807.76 |
DisclosureSEC source: 0000014272-19-000140 · wf-form4_156210197347296.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566.776 Underlying: Common Stock, $0.10 par value · 767.536 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 681.199 | $47.71 | $32,500.00 |
DisclosureSEC source: 0000014272-19-000094 · wf-form4_155423754602798.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,670.112 Underlying: Common Stock, $0.10 par value · 681.199 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,708.158 | $49.89 | $185,000.00 |
DisclosureSEC source: 0000014272-19-000032 · wf-form4_154940320796019.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,988.913 Underlying: Common Stock, $0.10 par value · 3,708.158 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 625.24 | $51.98 | $32,499.98 |
DisclosureSEC source: 0000014272-19-000012 · wf-form4_154655096964226.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,064.256 Underlying: Common Stock, $0.10 par value · 625.24 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2018 Filed Oct 3, 2018 01:42 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 523.518 | $62.08 | $32,500.00 |
DisclosureSEC source: 0000014272-18-000187 · wf-form4_153853093272601.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,439.016 Underlying: Common Stock, $0.10 par value · 523.518 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2018 Filed Jul 4, 2018 01:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 587.279 | $55.34 | $32,500.02 |
DisclosureSEC source: 0000014272-18-000152 · wf-form4_153066771197420.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,915.498 Underlying: Common Stock, $0.10 par value · 587.279 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 513.834 | $63.25 | $32,500.00 |
DisclosureSEC source: 0000014272-18-000101 · wf-form4_152278772768978.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,265.47 Underlying: Common Stock, $0.10 par value · 513.834 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,945.86 | $62.80 | $185,000.01 |
DisclosureSEC source: 0000014272-18-000044 · wf-form4_151787279657237.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,751.636 Underlying: Common Stock, $0.10 par value · 2,945.86 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 23:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 530.352 | $61.28 | $32,499.97 |
DisclosureSEC source: 0000014272-18-000020 · wf-form4_151502241512490.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,775.359 Underlying: Common Stock, $0.10 par value · 530.352 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:50 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 509.884 | $63.74 | $32,500.01 |
DisclosureSEC source: 0000014272-17-000186 · wf-form4_150706381075251.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,218.54 Underlying: Common Stock, $0.10 par value · 509.884 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:02 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 537.423 | $55.72 | $29,945.21 |
DisclosureSEC source: 0000014272-17-000154 · wf-form4_149929212647399.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,683.031 Underlying: Common Stock, $0.10 par value · 537.423 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 23:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 199.217 | $54.38 | $10,833.42 |
DisclosureSEC source: 0000014272-17-000119 · wf-form4_149134801586871.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,123.971 Underlying: Common Stock, $0.10 par value · 199.217 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 21, 2017 Filed Feb 24, 2017 00:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,924.754 | $54.78 | $160,218.02 |
DisclosureSEC source: 0000014272-17-000058 · wf-form4_148789616778457.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924.754 Underlying: Common Stock, $0.10 par value · 2,924.754 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2017 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,850 | $41.76 | $453,096.00 |
DisclosureSEC source: 0001209191-12-054064 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,873 F1 · price: Open market sales reported on this line occurred at a weighted average price of $41.76 (range $41.63 to $41.95). F2 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2012 Filed Jun 1, 2012 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-12-031706 · doc4.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 236,000 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007770 · doc4.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0001209191-12-007770 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,601 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 118,000 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039504 · doc4.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2021-07-12 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| May 25, 2011 Filed May 26, 2011 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,735 | $55.51 | $540,389.85 |
DisclosureSEC source: 0001209191-11-031209 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,400 F1 · price: Open market sales reported on this line occurred at a weighted average price of $55.51 (range $55.27 to $55.66). F2 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 40,600 | $38.08 | $1,546,048.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 3 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,601 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $38.08 (range $37.70 to $38.33). Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,900 | $37.11 | $478,719.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 2 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,201 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $37.11 (range $36.68 to $37.67). Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $36.39 | $90,975.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,101 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.39 (range $35.64 to $36.61). F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 236,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000008 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0000875320-11-000008 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,406 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 118,000 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000043 · edgar.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 354,000 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000009 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,000 Underlying: Common Stock · 354,000 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0000875320-10-000009 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,205 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 549,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000009 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,000 Underlying: Common Stock · 549,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 134,129 | $0.01 | $1,341.29 |
DisclosureSEC source: 0000875320-09-000009 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,129 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2012. Read SEC document |
| June 01, 2008 Filed Jun 2, 2008 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0000875320-08-000041 · edgar.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 16:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000066 · edgar.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2006 Filed Jun 2, 2006 17:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000053 · edgar.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 20,000 shares Expires 2016-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2005 Filed Jun 3, 2005 14:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0000875320-05-000027 · edgar.xml · derivative · entry 1 Emmens Matthew · CIK 0001298332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2015-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.